NCT05533411

A Study of Donanemab (LY3002813) in Healthy Chinese Participants

A Parallel-group Treatment, Phase 1, Participant- and Investigator-Blind, Randomized Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of Single Intravenous Dose of Donanemab Compared With Placebo in Healthy Chinese Participants

• Status: Completed
• Phase: Phase 1
• Study type: Interventional
• Enrollment: 36 (actual)
• Sponsor: Eli Lilly and Company · Industry
• Sex: All
• Age: 18 Years – 40 Years
• Healthy volunteers: Accepted

Summary

The main purpose of this study is to evaluate the safety and tolerability of donanemab (LY3002813) when administered as single dose in healthy Chinese participants. The study will also assess how fast donanemab gets into the blood stream and how long it takes the body to remove it. The study is open to healthy participants. The study will last up to approximately 85 days.

Conditions

• Healthy

Interventions

Type	Name	Description
DRUG	Donanemab	Administered IV.
DRUG	Placebo	Administered IV.

Timeline

• Start date: 2022-09-14
• Primary completion: 2023-01-05
• Completion: 2023-01-05
• First posted: 2022-09-09
• Last updated: 2024-10-04
• Results posted: 2024-10-04

Locations

2 sites across 1 country: China

Regulatory

• FDA-regulated drug study